logo
Labcorp Unveils AI Tool To Simplify Lab Test Selection

Labcorp Unveils AI Tool To Simplify Lab Test Selection

Forbes4 days ago
Labcorp announced yesterday a new AI tool called Test Finder to help doctors speed up their ability to locate the right lab tests. Built with Amazon Web Services, the system lets clinicians type or speak their questions and then shows a ranked list of the best-matching tests or assays. Instead of navigating through more than 5,000 test items, doctors can now find what they need in a matter of seconds.
"Clinicians are under increasing pressure to do more with less," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Test Finder is designed to ease that burden by providing a faster, more intuitive way to navigate complex test menus, conduct research and identify the right tests, so clinicians can focus on what matters most: their patients."
Fixing Complicated Processes
Nearly 70 percent of all medical decisions depend on lab results. Yet finding the right test often requires sorting through pages of similar-sounding options. The wrong choice can mean delays, added costs, or a misstep in treatment.
The system provides access to thousands of lab tests across many areas including oncology, women's health, neurology, autoimmune diseases, and other requested assays. The use of this AI assistant aims to cut the time spent placing complex orders by up to 70 percent. For example, it might have taken navigation across 15 to 20 screens to track down a rare endocrine test. Now, the natural language-powered assistant will allow you to locate it in seconds.
That time savings matters. A primary care doctor may see thirty or more patients a day, each with a different set of lab needs. The minutes add up quickly.
How the Tool Works
Test Finder runs on AWS Bedrock and draws on a language model trained for clinical terms and Labcorp's catalog. When a doctor enters a query, the AI looks at the patient's symptoms or suspected conditions, links them to diagnostic pathways, and lists the most relevant tests. Each option shows the name, purpose, specimen type, and the code needed to order it.
The software runs on AWS infrastructure that meets HIPAA security standards. Labcorp says patient data remains encrypted end to end.
An Industry Rush Toward AI
Labcorp isn't alone. Quest Diagnostics recently partnered with Google Cloud on similar AI projects in research and customer support. Academic hospitals are testing AI agents in pathology and radiology to spot anomalies in scans faster. These experiments all chase the same goal: give clinicians better information in less time.
Labcorp processes more than 700 million tests a year and supports most newly approved FDA therapies, so the company's rollout is likely to draw attention from other large diagnostic networks.
The Test Finder team plans to keep tuning the software. Labcorp says it will judge success by how much time doctors save, how satisfied they are with the experience, and whether diagnoses speed up.
"Test Finder is a powerful example of how we're using technology to simplify complexity," said Bola Oyegunwa, Ph.D., Labcorp's chief information and technology officer. "By integrating generative AI, we're not only improving the provider experience, we're laying the foundation for smarter, more connected healthcare solutions that scale with the needs of our customers."
AI Spreading Through Healthcare
AI is showing up almost everywhere in hospitals and clinics. A McKinsey survey from late 2024 found that 85 percent of healthcare executives were already using or actively testing AI systems for tasks ranging from insurance claims to patient scheduling.
In radiology, image-analysis platforms now scan for lung nodules and tumors before a radiologist ever opens the file. Some can flag suspicious findings in minutes, which can shave hours off the time to diagnosis. In drug discovery, tools like DeepMind's AlphaFold are helping scientists map protein structures faster than they could in the lab, cutting years off early-stage research.
On the administrative side, AI models handle coding and prior authorization paperwork. Health systems using these programs have reported review times dropping by 50 to 60 percent. That allows billing staff to focus on patient-facing tasks rather than combing through forms.
Patients are beginning to interact with AI, too. Chatbots now handle routine questions about medications or symptoms. Digital mental-health tools use conversational agents to track mood swings and suggest coping strategies, particularly in rural areas with few therapists.
Balancing AI Interest With Caution
Some clinicians have raised questions about the increasing use of AI, especially on private health data. Labcorp intends that the tool is meant to support, not replace, human judgment.
Doctors and regulators agree that AI needs strong guardrails. Algorithms can reflect the biases in the data they learn from, and mistakes in a medical setting can carry serious consequences. AI powered systems such as Test Finder are increasingly adding multiple checkpoints and ongoing audits as tools are rolled out.
Still, the appeal of using AI is clear. By making it faster to match a patient with the right test, the company hopes Test Finder will do more than ease paperwork. It could help doctors get to answers sooner, and that can change lives.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Can Super Micro's AI Demand Outpace Profit Margin Fears?
Can Super Micro's AI Demand Outpace Profit Margin Fears?

Yahoo

time7 minutes ago

  • Yahoo

Can Super Micro's AI Demand Outpace Profit Margin Fears?

Super Micro Computer (NASDAQ:SMCI) is navigating a complex market landscape as it prepares to report its fiscal fourth-quarter earnings with a significant long-term growth narrative in the AI server space tempered by immediate concerns about market visibility and sustained pressure on profit margins. The company's heavy reliance on key suppliers and a competitive environment, where large-scale deals and component costs weigh on profitability, creates a cautious outlook despite its strong position as a leading beneficiary of rising AI infrastructure spending. Analyst Matt Bryson of Wedbush, in a note released on Monday, reiterated a Neutral rating on Super Micro with a $30 price forecast ahead of the company's earnings report scheduled for August the analyst acknowledged Super Micro's positioning as a key beneficiary of accelerating AI infrastructure spend, particularly in the server market, he expressed caution over near-term visibility and uncertainty around actual demand strength. Bryson noted that Super Micro stands to benefit from secular trends that align with its core strengths. Spending from neocloud providers, AI model builders, and sovereign buyers continues to grow, and these customers are increasingly turning to OEMs like Super Micro and Dell Technologies (NYSE:DELL) to meet their AI server requirements. He added that Nvidia's (NASDAQ:NVDA) apparent prioritization of GB200 deliveries to OEMs, rather than directly to hyperscalers, could serve as a tailwind for Super Micro. Peer company Gigabyte, for example, recently reported a 50% quarter-over-quarter sales surge, a result Bryson attributed to increased AI server shipments. If current market dynamics hold, Bryson sees a long-term path for Super Micro to potentially reach $10 billion in quarterly sales, echoing targets previously laid out by Super Micro CEO Charles Liang. This would be a significant leap from the $5.9 billion revenue consensus for fiscal fourth quarter and the $6.4 billion projection for calendar first quarter. However, Bryson underscored that visibility into Super Micro's actual build and demand trends remains limited. The company's heavy reliance on related parties for component sourcing and manufacturing complicates tracking real-time activity. Additionally, data from third-party sources has yet to reflect the level of demand surge expected from recent AI server trends. While strength in Taiwan-based suppliers like Wistron suggests a robust upstream environment, Bryson's team has not been able to confirm that Super Micro is directly seeing similar momentum in its own sales funnel. Margins also remain a key concern. Gross margins are expected to stay under pressure in the near term due to an increasing share of Nvidia (NASDAQ:NVDA) content in Super Micro's bill of materials. According to conversations with ODMs and OEMs, GB200-based designs leave little room for differentiation, further compressing vendor margins. Management has guided fiscal fourth-quarter gross margins to remain around 10%, roughly in line with the 9.7% margin reported in the previous quarter. The analyst characterized this conservatism as prudent, citing the lower-margin profile of large-scale deals, rising Nvidia component costs, and a lack of meaningful relief in memory pricing. For the fiscal fourth quarter, Super Micro management projected revenue in the range of $5.6 billion to $6.4 billion and adjusted earnings per share between 40 cents and 50 cents. Operating expenses are expected to reach $245 million, with an adjusted tax rate of 16.5%. The fully diluted share count is projected at 642 million, and capital expenditures are guided between $45 million and $55 million. Despite Super Micro's significant share price appreciation over the past few months, Bryson remains on the sidelines. Price Action: SMCI shares were trading higher by 3.88% to $58.84 at last check Monday. Image via Shutterstock Latest Ratings for SMCI Date Firm Action From To May 2021 Susquehanna Maintains Positive May 2021 Northland Capital Markets Maintains Outperform Jun 2020 Northland Capital Markets Initiates Coverage On Outperform View More Analyst Ratings for SMCI View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? SUPER MICRO COMPUTER (SMCI): Free Stock Analysis Report This article Can Super Micro's AI Demand Outpace Profit Margin Fears? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

JPMorgan drops 3-word verdict on Amazon stock post-earnings
JPMorgan drops 3-word verdict on Amazon stock post-earnings

Yahoo

time7 minutes ago

  • Yahoo

JPMorgan drops 3-word verdict on Amazon stock post-earnings

JPMorgan drops 3-word verdict on Amazon stock post-earnings originally appeared on TheStreet. Amazon () posted a superb Q2 on paper, but the market was mostly unfazed. Shares pulled back sharply, with investors fixating on Amazon Web Services (AWS) relatively lagging in growth. However, in that cloud of concern (no pun intended), JPMorgan sees an opening, not noise. 💵💰💰💵 Veteran Analyst Doug Anmuth's call effectively cuts through the volatility, while putting fresh focus on how Wall Street's top desks are interpreting Amazon's long-term AI and infrastructure story. Amazon's big AI bet tests investor patience Amazon's Q2 results showed a clear contrast in booming top-line expansion, massive investment on one side, and investor unease on the other. Overall sales jumped a superb 13% amounting to $167.7 billion, beating estimates by an eye-popping $5.60 net income surged, with a $1.68 EPS, blowing past estimates by 36 cents. However, all eyes were on AWS sales, which were relatively uninspiring. AWS sales grew 17.5% to $30.9 billion, but remarkably lagged the headline-grabbing growth at competitors. Putting things in perspective, Microsoft Azure posted a 39% jump, while Google Cloud surged 32%, reinforcing fears that AWS may be losing ground in the AI cloud race. Margins told a similar story. AWS operating margin fell sharply to 32.9%, down from 39.5% the prior quarter. Management attributed the squeeze to its aggressive GenAI investments and infrastructure hiccups, particularly with power, chip supply, and server yields. What turned heads, though, was the spending. Amazon's capital expenditures came in at a record $31.4 billion, up close to 90% year-over-year. That's a remarkably high number, especially with management calling it 'reasonably representative' of what's to come in the back half of the year. However, the goal at this point is clear, and it involves scaling AWS's infrastructure quick enough to support AI ambitions and relieve capacity strain. Wall Street wasn't sold, with concerns centering around AWS's slower growth, thinner margins, and unclear near-term return on the hefty capex. Still, CEO Andy Jassy defended the strategy. He emphasized that Amazon is still in the early innings of its powerful multi-year AI journey and that capacity constraints will ease as new infrastructure comes online. JPMorgan's three-word response on Amazon stock: Buy the pullback As previously mentioned, Amazon may have delivered on paper, but the market didn't see it that way. Amazon stock tanked over 8% on Aug. 1, but it clawed back some of those losses pre-market Aug. 4. Still, the initial drop raises some major questions. Nevertheless, one top voice on the Street isn't analyst Doug Anmuth at JPMorgan feels the dip is exactly when investors should move in. He feels investors should 'Buy the pullback,' backing up his Buy rating on Amazon stock, while boosting his price target from $255 to $265, implying a superb upside of 23% from current levels. So what triggered the drop? According to Anmuth, the culprit was AWS. While AWS revenue jumped 17.5% year-over-year to $30.9 billion, it underwhelmed investors who expected more, especially considering the backdrop of AI-fueled cloud expansion. That's not all. Amazon also reported a record $31.4 billion in capex, which only made matters worse in compounding the pressure on AWS to deliver even bigger growth numbers. Still, the Street isn't backing off. Analysts at Citi also bumped their price target on the stock to $270, noting Amazon's higher spending reflects healthy demand and efforts to fix infrastructure constraints in the cloud. However, it's important to consider that growth lagged peers, and management didn't exactly calm concerns around the AI opportunity. Despite that, the Wall Street punditry believes the selloff doesn't match the broader story. And for JPMorgan, this is the kind of dip worth loading up on. AWS: Amazon's profit engine and AI powerhouse AWS is far from purely a segment; it's arguably the profit core and strategic anchor for the entire business. It's responsible for close to 60% of Amazon's operating income, with AWS running at an annualized sales pace above $123 billion. That scale gives it the profile of a standalone cloud giant, one that underpins the bulk of Amazon's enterprise Andy Jassy has reiterated AWS's incredible competitive moat, noting it's still 'meaningfully larger' than its next-closest rival. Recent data supports that lead. Per the most recent reports, AWS commands roughly 31% to 32% of the global cloud infrastructure market, followed closely by Microsoft Azure with roughly 22.5% to 24%, and Google Cloud at 10% to 12%. Other estimates tend to vary based on methodology, but generally confirm AWS's position at the top, with competitors trailing by a hefty margin. AI is rapidly deepening that role. AWS is investing a ton of money in generative and agentic AI, in serving external clients through the Generative AI Innovation Center. Another key differentiator for AWS is that it effectively originates from Amazon's internal infrastructure needs before commercialization. It comes with embedded efficiency and noteworthy cash-flow sustainability, making it more than a cost center, powering internal tools like Amazon Personalize. That synergy creates a robust loop where AI sharpens retail engagement and fuels more demand for compute. More News: Amazon's quiet pricing twist on tariffs stuns shoppersBank of America flags 3 breakout stocks to watch ahead of earnings Margins may have compressed recently on the back of AWS building its custom infrastructure, including Trainium chips, but those bets are about long-term dominance. JPMorgan drops 3-word verdict on Amazon stock post-earnings first appeared on TheStreet on Aug 4, 2025 This story was originally reported by TheStreet on Aug 4, 2025, where it first appeared.

TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos
TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos

Yahoo

time7 minutes ago

  • Yahoo

TSLA: Tesla Approves $29 Billion For Musk Amid Falling Sales, Legal Chaos

Aug 4 - Tesla (NASDAQ:TSLA) is not shy about betting big on Elon Musk. The company just approved a fresh 96 million-share compensation package for its CEO, worth around $29 billion. It's all about keeping Musk locked in, especially after a Delaware court tossed out his original $50 billion pay deal from 2018, calling it unfair to shareholders. Now, Musk is fighting that ruling in court. But in the meantime, Tesla's board put together a new plan. The shares won't vest unless Musk stays in a top executive role through 2027, and even then, they come with a five-year holding period. Tesla also says there won't be any double-dipping if his old package gets reinstated. All this is happening while Tesla faces real challenges. Sales are down, the Cybertruck hasn't delivered, and competition from legacy automakers like General Motors (NYSE:GM), Hyundai (HYMTF), and BMW (BMWYY) is heating up. On top of that, Musk's political moves haven't helped Tesla's brand loyalty. Still, this new award could help steady the ship, at least if Musk sticks around. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store